364 related articles for article (PubMed ID: 25559408)
1. Severe Hypocalcemia Associated With Denosumab in Metastatic Castration-Resistant Prostate Cancer: Risk Factors and Precautions for Treating Physicians.
Autio KA; Farooki A; Glezerman IG; Chan A; Schneider CW; Barr HC; Seyboth BM; Kampel LJ; Danila DC; Rathkopf DE; Slovin SF; Scher HI; Morris MJ
Clin Genitourin Cancer; 2015 Aug; 13(4):e305-e309. PubMed ID: 25559408
[No Abstract] [Full Text] [Related]
2. A RANKL Wrinkle: Denosumab-Induced Hypocalcemia.
Laskowski LK; Goldfarb DS; Howland MA; Kavcsak K; Lugassy DM; Smith SW
J Med Toxicol; 2016 Sep; 12(3):305-8. PubMed ID: 26987988
[TBL] [Abstract][Full Text] [Related]
3. High serum ALP level is associated with increased risk of denosumab-related hypocalcemia in patients with bone metastases from solid tumors.
Kinoshita Y; Arai M; Ito N; Takashi Y; Makita N; Nangaku M; Shinoda Y; Fukumoto S
Endocr J; 2016 May; 63(5):479-84. PubMed ID: 26860123
[TBL] [Abstract][Full Text] [Related]
4. Denosumab-Associated Severe Hypocalcemia in a Patient With Chronic Kidney Disease.
Salim SA; Nair LR; Thomas L; Garla V; Palabindala V; Agarwal M; Fülöp T
Am J Med Sci; 2018 May; 355(5):506-509. PubMed ID: 29753381
[TBL] [Abstract][Full Text] [Related]
5. Harnessing the potential of therapeutic agents to safeguard bone health in prostate cancer.
Miller K; Steger GG; Niepel D; Lüftner D
Prostate Cancer Prostatic Dis; 2018 Nov; 21(4):461-472. PubMed ID: 29988100
[TBL] [Abstract][Full Text] [Related]
6. Prolonged Hypocalcemia Following a Single Dose of Denosumab for Diffuse Bone Metastasis of Gastric Cancer after Total Gastrectomy.
Iizumi S; Shimoi T; Nishikawa T; Kitano A; Sasada S; Shimomura A; Noguchi E; Yunokawa M; Yonemori K; Shimizu C; Fujiwara Y; Tamura K
Intern Med; 2017 Nov; 56(21):2879-2882. PubMed ID: 28943574
[TBL] [Abstract][Full Text] [Related]
7. Effect of denosumab versus zoledronic acid on calcium levels in cancer patients with bone metastasis: A retrospective cohort study.
Nasser SM; Sahal A; Hamad A; Elazzazy S
J Oncol Pharm Pract; 2019 Dec; 25(8):1846-1852. PubMed ID: 31694497
[TBL] [Abstract][Full Text] [Related]
8. Incidence of hypocalcemia in patients receiving denosumab for prevention of skeletal-related events in bone metastasis.
Yerram P; Kansagra S; Abdelghany O
J Oncol Pharm Pract; 2017 Apr; 23(3):179-184. PubMed ID: 26830549
[TBL] [Abstract][Full Text] [Related]
9. Excess of second tumors in denosumab-treated patients: a metabolic hypothesis.
Tovazzi V; Dalla Volta A; Pedersini R; Amoroso V; Berruti A
Future Oncol; 2019 Jul; 15(20):2319-2321. PubMed ID: 31237145
[No Abstract] [Full Text] [Related]
10. Severe and prolonged hypocalcemia after a single dose of denosumab for metastatic breast cancer with diffuse bone involvement without prior calcium/vitamin D supplementations.
Uhm SJ; Hall JA; Herrington JD
J Oncol Pharm Pract; 2021 Jul; 27(5):1287-1290. PubMed ID: 33081580
[TBL] [Abstract][Full Text] [Related]
11. Organic anxiety in a woman with breast cancer receiving denosumab.
Lin KF; Chen KH; Huang WL
Gen Hosp Psychiatry; 2015; 37(2):192.e7-8. PubMed ID: 25772947
[TBL] [Abstract][Full Text] [Related]
12. Prolonged hypocalcemia following denosumab therapy in metastatic hormone refractory prostate cancer.
Milat F; Goh S; Gani LU; Suriadi C; Gillespie MT; Fuller PJ; Teede HJ; Strickland AH; Allan CA
Bone; 2013 Aug; 55(2):305-8. PubMed ID: 23685544
[TBL] [Abstract][Full Text] [Related]
13. Hypocalcemia in a Patient with Cancer.
Rosner MH
Clin J Am Soc Nephrol; 2017 Apr; 12(4):696-699. PubMed ID: 28274993
[No Abstract] [Full Text] [Related]
14. Hypocalcaemia in patients with metastatic bone disease treated with denosumab.
Body JJ; Bone HG; de Boer RH; Stopeck A; Van Poznak C; Damião R; Fizazi K; Henry DH; Ibrahim T; Lipton A; Saad F; Shore N; Takano T; Shaywitz AJ; Wang H; Bracco OL; Braun A; Kostenuik PJ
Eur J Cancer; 2015 Sep; 51(13):1812-21. PubMed ID: 26093811
[TBL] [Abstract][Full Text] [Related]
15. Safety of long-term denosumab therapy: results from the open label extension phase of two phase 3 studies in patients with metastatic breast and prostate cancer.
Stopeck AT; Fizazi K; Body JJ; Brown JE; Carducci M; Diel I; Fujiwara Y; Martín M; Paterson A; Tonkin K; Shore N; Sieber P; Kueppers F; Karsh L; Yardley D; Wang H; Maniar T; Arellano J; Braun A
Support Care Cancer; 2016 Jan; 24(1):447-455. PubMed ID: 26335402
[TBL] [Abstract][Full Text] [Related]
16. Life-threatening sustained hypocalcemia following Denosumab use in metastatic prostate cancer.
Patell K; Ajay K; Al Armashi AR; Bawwab A; Ravakhah K
J Oncol Pharm Pract; 2022 Apr; 28(3):698-702. PubMed ID: 34693819
[TBL] [Abstract][Full Text] [Related]
17. Identification of risk factors and development of detection algorithm for denosumab-induced hypocalcaemia.
Imatoh T; Sai K; Takeyama M; Hori K; Karayama M; Furuhashi K; Segawa K; Kimura M; Kawakami J; Saito Y
J Clin Pharm Ther; 2019 Feb; 44(1):62-68. PubMed ID: 30144112
[TBL] [Abstract][Full Text] [Related]
18. Denosumab-associated hypocalcaemia: incidence, severity and patient characteristics in a tertiary hospital setting.
Huynh AL; Baker ST; Stewardson AJ; Johnson DF
Pharmacoepidemiol Drug Saf; 2016 Nov; 25(11):1274-1278. PubMed ID: 27255807
[TBL] [Abstract][Full Text] [Related]
19. Life-threatening hypocalcaemia associated with denosumab in advanced chronic kidney disease.
Killen JP; Yong K; Luxton G; Endre Z
Intern Med J; 2016 Jun; 46(6):746-7. PubMed ID: 27257154
[No Abstract] [Full Text] [Related]
20. Risk Analysis of Denosumab-Induced Hypocalcemia in Bone Metastasis Treatment: Renal Dysfunction Is Not a Risk Factor for Its Incidence in a Strict Denosumab Administration Management System with Calcium/Vitamin D Supplementation.
Saito Y; Takekuma Y; Komatsu Y; Sugawara M
Biol Pharm Bull; 2021; 44(12):1819-1823. PubMed ID: 34853264
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]